Preclinical antitumor activity of the oral platinum analog satraplatin

详细信息    查看全文

• 作者：Katja Wosikowski ; Lou Lamphere ; Gerhard Unteregger ; Volker Jung ; Faith Kaplan ; Jimmy P. Xu ; Benno Rattel and Maureen Caligiuri
• 关键词：Satraplatin ; JM ; 118 ; Platinum ; Prostate cancer ; Drug resistance
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2007
• 出版时间：September, 2007
• 年：2007
• 卷：60
• 期：4
• 页码：589-600
• 全文大小：546 KB
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Pharmacology and Toxicology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0843

文摘

Purpose Satraplatin is an orally available platinum analog. The purpose of this study was to better characterize satraplatin’s preclinical antitumor efficacy in a variety of sensitive and resistant human tumor cell lines and in a prostate cancer xenograft model and to evaluate the effect of satraplatin on PSA expression and/or secretion in a prostate cancer cell line.